NBIX vs SCM · P/E 45, rev $1.77B vs P/E 10, rev $97.8M
Neurocrine Biosciences Inc (NBIX) versus Stellus Capital Investment (SCM) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Stellus Capital Investment (SCM) is a asset management company listed on NYSE.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported SCM revenue for 2025-12-31 was $97.8M. Net income was $27.0M. Revenue was down 2.1% from 2024-12-31 to 2025-12-31. SCM currently screens at market cap $244.6M and trailing P/E 10.2.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. SCM currently screens at market cap $244.6M and trailing P/E 10.2.
Not investment advice. Open the NBIX and SCM stock pages for the full models.
Not investment advice.